Anika Therapeutics announces excellent results from CINGAL phase 3 trial for knee osteoarthritis Anika Therapeutics, Inc informations . Earlier this year, Anika announced excellent results from CINGAL 13-01, a randomized, double-blind, placebo-controlled Stage 3 study, which demonstrated the efficacy and basic safety of a single injection of CINGAL for treatment of discomfort caused by OA of the knee. Charles H. Sherwood, President and CEO of Anika Therapeutics. KlegermanThe CINGAL 13-02 research enrolled 242 individuals from the CINGAL 13-01 research who had received an initial injection of CINGAL, MONOVISC, or saline. In the follow-up CINGAL 13-02 study, the participants received an open-label injection of CINGAL and were monitored for adverse events .2 percent) experienced a detrimental event linked to the study injection.